Leerink Partnrs Issues Pessimistic Outlook for MDGL Earnings

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) – Stock analysts at Leerink Partnrs cut their FY2026 earnings per share estimates for Madrigal Pharmaceuticals in a research report issued to clients and investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now anticipates that the biopharmaceutical company will earn $1.63 per share for the year, down from their previous estimate of $1.72. The consensus estimate for Madrigal Pharmaceuticals’ current full-year earnings is ($23.64) per share.

Other research analysts also recently issued research reports about the company. JMP Securities restated a “market outperform” rating and issued a $427.00 price objective on shares of Madrigal Pharmaceuticals in a research note on Friday, January 10th. Cantor Fitzgerald restated a “neutral” rating on shares of Madrigal Pharmaceuticals in a research note on Wednesday, November 20th. UBS Group upped their price objective on Madrigal Pharmaceuticals from $411.00 to $441.00 and gave the company a “buy” rating in a research note on Friday, November 1st. Oppenheimer reduced their price objective on Madrigal Pharmaceuticals from $375.00 to $350.00 and set an “outperform” rating for the company in a research note on Wednesday, October 23rd. Finally, StockNews.com upgraded Madrigal Pharmaceuticals to a “sell” rating in a research note on Saturday, October 12th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $351.67.

Madrigal Pharmaceuticals Trading Up 0.7 %

Shares of Madrigal Pharmaceuticals stock opened at $332.72 on Friday. The stock has a fifty day simple moving average of $314.39 and a 200 day simple moving average of $277.02. Madrigal Pharmaceuticals has a 12-month low of $168.25 and a 12-month high of $368.29. The company has a market capitalization of $7.26 billion, a P/E ratio of -13.27 and a beta of -0.38. The company has a current ratio of 5.98, a quick ratio of 5.93 and a debt-to-equity ratio of 0.15.

Insider Buying and Selling at Madrigal Pharmaceuticals

In other Madrigal Pharmaceuticals news, CEO William John Sibold sold 1,584 shares of the firm’s stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $335.24, for a total value of $531,020.16. Following the sale, the chief executive officer now owns 54,303 shares of the company’s stock, valued at $18,204,537.72. This trade represents a 2.83 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Robert E. Waltermire sold 103 shares of the firm’s stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $335.24, for a total value of $34,529.72. Following the completion of the sale, the vice president now directly owns 4,955 shares in the company, valued at approximately $1,661,114.20. The trade was a 2.04 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 12,090 shares of company stock valued at $3,883,621 in the last 90 days. Corporate insiders own 22.80% of the company’s stock.

Hedge Funds Weigh In On Madrigal Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Nisa Investment Advisors LLC increased its position in shares of Madrigal Pharmaceuticals by 47.6% during the 3rd quarter. Nisa Investment Advisors LLC now owns 211 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 68 shares during the last quarter. Kohmann Bosshard Financial Services LLC bought a new position in shares of Madrigal Pharmaceuticals during the 4th quarter valued at about $70,000. Quest Partners LLC increased its position in shares of Madrigal Pharmaceuticals by 172.8% during the 3rd quarter. Quest Partners LLC now owns 581 shares of the biopharmaceutical company’s stock valued at $123,000 after purchasing an additional 368 shares during the last quarter. KBC Group NV increased its position in shares of Madrigal Pharmaceuticals by 73.5% during the 4th quarter. KBC Group NV now owns 609 shares of the biopharmaceutical company’s stock valued at $188,000 after purchasing an additional 258 shares during the last quarter. Finally, Miracle Mile Advisors LLC bought a new position in shares of Madrigal Pharmaceuticals during the 4th quarter valued at about $216,000. 98.50% of the stock is currently owned by institutional investors.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.